Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.

[1]  E. Sokol,et al.  Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. , 2023, European urology oncology.

[2]  M. Gleave,et al.  Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial. , 2023, Journal of the National Cancer Institute.

[3]  M. Oberley,et al.  Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers. , 2023, JCO precision oncology.

[4]  J. Yin,et al.  Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study. , 2023, Archives of pathology & laboratory medicine.

[5]  Macie J. Rubin,et al.  Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. , 2023, European journal of cancer.

[6]  M. Pan,et al.  Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System. , 2023, Journal of Clinical Oncology.

[7]  C. Hwang,et al.  Molecular features and race‐associated outcomes of SPOP‐mutant metastatic castration‐resistant prostate cancer , 2023, The Prostate.

[8]  M. Santoni,et al.  Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future? , 2022, Cancers.

[9]  N. Agarwal,et al.  SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  R. Cathomas,et al.  Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs , 2022, Research and reports in urology.

[11]  Hai Huang,et al.  Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer , 2022, Frontiers in Oncology.

[12]  C. Sternberg,et al.  Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. , 2022, European journal of cancer.

[13]  J. Carles,et al.  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.

[14]  F. Saad,et al.  Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. , 2022, The New England journal of medicine.

[15]  T. Powles,et al.  Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial , 2022, Nature Medicine.

[16]  J. Theurillat,et al.  SPOP-mutant prostate cancer: Translating fundamental biology into patient care. , 2021, Cancer letters.

[17]  Xingchen Peng,et al.  Clinicopathological and prognostic significance of speckle-type POZ protein in cancers: a systematic review and meta-analysis , 2021, Cancer cell international.

[18]  E. Antonarakis,et al.  Clinical and genomic features of SPOP‐mutant prostate cancer , 2021, The Prostate.

[19]  F. Bray,et al.  Epidemiology and Prevention of Prostate Cancer. , 2021, European urology oncology.

[20]  M. Salido,et al.  SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence , 2021, The Prostate.

[21]  Jonathan E. Shoag,et al.  Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. , 2021, The Journal of clinical investigation.

[22]  E. Antonarakis,et al.  Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone‐sensitive prostate cancer , 2021, The Prostate.

[23]  Yundong He,et al.  Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression , 2021, Cancer Research.

[24]  S. Carr,et al.  Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer , 2020, Nature Communications.

[25]  N. Agarwal,et al.  Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. , 2020, European urology.

[26]  S. Lehrer,et al.  Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer , 2020, American journal of clinical oncology.

[27]  P. Kantoff,et al.  Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer , 2020, Clinical Cancer Research.

[28]  Jonathan E. Shoag,et al.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer. , 2020, Urologic oncology.

[29]  A. Clark,et al.  SPOP and cancer: a systematic review. , 2020, American journal of cancer research.

[30]  S. Tomlins,et al.  CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer , 2020, Clinical Cancer Research.

[31]  Haojie Huang,et al.  Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly , 2019, Molecular Cancer.

[32]  K. Fizazi,et al.  Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study , 2019, Annals of Oncology.

[33]  M. Zelefsky,et al.  Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients. , 2019, Journal of Clinical Oncology.

[34]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[35]  R. Nussbaum,et al.  Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines , 2019, JAMA oncology.

[36]  M. Kattan,et al.  Guidelines for Reporting of Statistics for Clinical Research in Urology , 2019, The Journal of urology.

[37]  P. Schellhammer,et al.  Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens , 2018, The Journal of urology.

[38]  M. Rubin,et al.  SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity , 2018, Clinical Cancer Research.

[39]  Jonathan E. Shoag,et al.  Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer , 2018, JCO precision oncology.

[40]  David R. Liu,et al.  Abstract 4350: Integrative and multiregional molecular analysis of localized, high grade prostate cancer treated with neoadjuvant androgen deprivation treatment , 2018, Molecular and Cellular Biology / Genetics.

[41]  G. Freeman,et al.  Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance , 2017, Nature.

[42]  Yonghe Li,et al.  Abstract 2702: Mutations ofSPOP,FOXA1andIDH1are associated with prostate cancer metastasis and biochemical outcomes , 2017 .

[43]  M. Rubin,et al.  SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. , 2017, Cancer cell.

[44]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[45]  B. Trock,et al.  Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. , 2015, European urology.

[46]  Paola Lecca,et al.  SPOP mutation leads to genomic instability in prostate cancer , 2015, eLife.

[47]  C. Tufanaru,et al.  Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness , 2015, International journal of evidence-based healthcare.

[48]  W. Isaacs,et al.  Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. , 2015, European urology.

[49]  J. López-Guerrero,et al.  Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer. , 2014, European journal of cancer.

[50]  S. Carr,et al.  Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer , 2014, Science.

[51]  K. Rajapakshe,et al.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. , 2014, Cancer research.

[52]  P. Warde,et al.  Pre-treatment risk stratification of prostate cancer patients: A critical review. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[53]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[54]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[55]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[56]  Kurex Sidik,et al.  A simple confidence interval for meta‐analysis , 2002, Statistics in medicine.

[57]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[58]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[59]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[60]  A. Jemal,et al.  Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. , 2019, European urology.

[61]  H. Hieronymus,et al.  SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.